Rein Therapeutics

Rein Therapeutics operates as a clinical-stage biopharmaceutical company developing treatments for orphan pulmonary and fibrosis indications. LTI-01, a proenzyme, has completed Phase 1b and Phase 2a clinical trials for treating loculated pleural effusions.

LTI-03 is an inhaled peptide based on Caveolin-1 biology that inhibits lung scarring while preserving alveolar progenitor cells critical for tissue repair and regeneration. The randomized, placebo-controlled RENEW Phase 2 study of LTI-03 evaluates the drug in patients with idiopathic pulmonary fibrosis. Approved therapies for idiopathic pulmonary fibrosis can slow the disease in some patients but do not halt or reverse it.